AZ doses first participants with COVID-19 variant vaccine
AstraZeneca (AZ) has announced that the first participants have been vaccinated as part of a Phase II/III trial testing a new COVID-19 variant vaccine – AZD2816. The trial, which is set to recruit approximately 2,250 participants, will administer AZD2816 to individuals who have been previously vaccinated with AZ’s authorised COVID-19 vaccine Vaxzevria or an mRNA vaccine, at least three months after their last dose.
PharmaTimes - June 28, 2021View the full story here: http://www.pharmatimes.com/news/az_doses_first_participants_with_covid-19_variant_vaccine_1372293